Rational for an early treatment of multiple sclerosis;Fundamento racional para el tratamiento precoz de la esclerosis multiple

Revista de Neurologia

Volumn 30, Issue 12, 2000, Pages 1265-1268

  Comi, G ^a,b   Martino, G ^a  

^a Instituto Científico San Rafael   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Copolymer 1; Early treatment; IFN ; Immunomodulatory drugs; Multiple sclerosis

Indexed keywords

BETA INTERFERON; COPOLYMER; IMMUNOMODULATING AGENT;

CONFERENCE PAPER; DEMYELINATING DISEASE; DISEASE COURSE; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PHYSICAL ACTIVITY; RELAPSE; RISK BENEFIT ANALYSIS;

EID: 0034674196     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3012.2000018     Document Type: Conference Paper

References (35)

1. Martina R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-87.
2. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85: 299-302.
3. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci USA 1996; 93: 2253-6.
4. Polman CH, Hartung HP. The treatment of multiple sclerosis: current and future. Curr Opin Neurol 1995; 8: 200-9.
5. The IFNB Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al, for The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
7. Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al, for the Copolymer 1 Multiple Sclerosis Study Group. Ex-tended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-8.
9. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15.
10. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994; 91: 4872-6.
11. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-94.
12. Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L, et al. Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998; 43: 332-9.
13. Kappos L, Moeri D, Radue EW, Schoetzau A, Barkhof F, Miller DH, et al. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability/impairment in multiple sclerosis: a metaanalysis. Lancet 1999. (In press).
14. Koudriavtseva T, Thompson AJ, Fiorelli M, Gasperini C, Bastianello S, Bozzao A, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62: 285-7.
15. Filippi M, Horsfield MA, Morissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635-41.
16. European Study Group on Interferon b-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
17. Jacobs LD, Kaba SE, Miller CM, Piore RL, Brownscheidle CM. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997; 41: 392-8.
18. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al, for The Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-9.
19. Paolino E, Fainardi E, Ruppi P, Tola MR, Govoni V, Casetta I, et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 572-5.
20. O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503.
21. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-8.
22. Optic Neuritis Study Group. The 5-year risk of multiple sclerosis after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997; 49: 1404-13.
23. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997; 99: 1682-90.
24. Lucchinetti CF, Bruck W, Rodríguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-74.
25. Khan OA, Dhib-Jalbut SS. Serum interferon beta-la (Avonex) levels following intramuscular injection in relapsing-remitting multiple sclerosis patients. Neurology 1998; 51: 738-42.
26. Khan OA, Xia Q, Bever CT Jr, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996; 46: 1639-43.
27. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 1997; 10: 186-92.
28. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lasmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
29. Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, et al. Comparison of multiple sclerosis clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999; 52: 588-94.
30. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayana S, Francis GS, et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
31. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
32. Comi G, Barkhoff F, Durelli L, Edon G, Fernández O, Filippi M, et al. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Multiple Sclerosis 1995; 1: S24-7.
33. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
34. Wienshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989; 112: 1419-28.
35. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-56.